Related references
Note: Only part of the references are listed.Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial
Alessandro Rambaldi et al.
LANCET ONCOLOGY (2015)
How I manage sinusoidal obstruction syndrome after haematopoietic cell transplantation
Enric Carreras
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT
Corey Cutler et al.
BLOOD (2014)
Allogeneic hematopoietic SCT for adults AML using i.v. BU in the conditioning regimen: outcomes and risk factors for the occurrence of hepatic sinusoidal obstructive syndrome
A. Nagler et al.
BONE MARROW TRANSPLANTATION (2014)
Reduced-toxicity conditioning prior to allogeneic stem cell transplantation improves outcome in patients with myeloid malignancies
Claire Oudin et al.
HAEMATOLOGICA (2014)
Multi-Institutional Study of Post-Transplantation Cyclophosphamide As Single-Agent Graft-Versus-Host Disease Prophylaxis After Allogeneic Bone Marrow Transplantation Using Myeloablative Busulfan and Fludarabine Conditioning
Christopher G. Kanakry et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI
Edward A. Copelan et al.
BLOOD (2013)
Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation
Christopher Bredeson et al.
BLOOD (2013)
Randomized Trial of Myeloablative Conditioning Regimens: Busulfan Plus Cyclophosphamide Versus Busulfan Plus Fludarabine
Je-Hwan Lee et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Allogeneic Hematopoietic Stem-Cell Transplantation for Acute Myeloid Leukemia in Remission: Comparison of Intravenous Busulfan Plus Cyclophosphamide (Cy) Versus Total-Body Irradiation Plus Cy As Conditioning Regimen-A Report From the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation
Arnon Nagler et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study
Hui Liu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2013)
A disease risk index for patients undergoing allogeneic stem cell transplantation
Philippe Armand et al.
BLOOD (2012)
Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS
S. M. Luger et al.
BONE MARROW TRANSPLANTATION (2012)
Myeloablative Reduced-Toxicity i.v. Busulfan-Fludarabine and Allogeneic Hematopoietic Stem Cell Transplant for Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome in the Sixth through Eighth Decades of Life
Gheath Alatrash et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2011)
The Incidence of Veno-Occlusive Disease Following Allogeneic Hematopoietic Stem Cell Transplantation Has Diminished and the Outcome Improved over the Last Decade
Enric Carreras et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2011)
Comorbidity index does not predict outcome in allogeneic myeloablative transplants conditioned with fludarabine/i.v. busulfan (FluBu4)
P. Patel et al.
BONE MARROW TRANSPLANTATION (2011)
Long-Term Prognosis of Acute Myeloid Leukemia According to the New Genetic Risk Classification of the European LeukemiaNet Recommendations: Evaluation of the Proposed Reporting System
Christoph Roellig et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Reduced Mortality after Allogeneic Hematopoietic-Cell Transplantation.
Ted A. Gooley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Transplantation from matched siblings using once-daily intravenous busulfan/fludarabine with thymoglobulin: A myeloablative regimen with low nonrelapse mortality in all but older patients with high-risk disease
James A. Russell et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2008)
Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS
Borje S. Andersson et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2008)
Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation:: Chronic graft-versus-host disease is the strongest factor improving survival
David Valcarel et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Hematopoietic cell transplantation-specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences
Mohamed L. Sorror et al.
BLOOD (2007)
Fludarabine and busulfan as a myeloablative conditioning regimen for allogeneic stem cell transplantation in high- and standard-risk leukemic patients
M. Iravani et al.
BONE MARROW TRANSPLANTATION (2007)
Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: A comparison with an every 6-hour dosing schedule
Timothy Madden et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2007)
Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using BLA-identical sibling donors in myelodysplastic syndromes
Rodrigo Martino et al.
BLOOD (2006)
A risk score for mortality after allogeneic hematopoietic cell transplantation
T Parimon et al.
ANNALS OF INTERNAL MEDICINE (2006)
Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS
M de Lima et al.
BLOOD (2004)
Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia
BD Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia:: disease status by marrow blasts is the strongest prognostic factor
HG Sayer et al.
BONE MARROW TRANSPLANTATION (2003)
Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: Study of pharmacokinetics and early clinical outcomes
JA Russell et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2002)
Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: Decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality
A Kashyap et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2002)
Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: A phase II study
BS Andersson et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2002)
Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia:: long-term follow-up of 4 randomized studies
G Socié et al.
BLOOD (2001)
Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects
PA McSweeney et al.
BLOOD (2001)
Acute safety and pharmacokinetics of intravenous busulfan when used with oval busulfan and cyclophosphamide as pretransplantation conditioning therapy: A phase I study
BS Andersson et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2000)
Share Paper
